Do We Have Sufficient Evidence to Define Prognosis for "Low-grade" Fumarate Hydratase-deficient Renal Cell Carcinoma?

Adv Anat Pathol. 2022 May 1;29(3):178-181. doi: 10.1097/PAP.0000000000000335.
No abstract available

Publication types

  • Comment

MeSH terms

  • Carcinoma, Renal Cell* / diagnosis
  • Carcinoma, Renal Cell* / enzymology
  • Carcinoma, Renal Cell* / pathology
  • Female
  • Fumarate Hydratase* / deficiency
  • Fumarate Hydratase* / genetics
  • Humans
  • Kidney Neoplasms* / diagnosis
  • Kidney Neoplasms* / enzymology
  • Kidney Neoplasms* / pathology
  • Leiomyomatosis* / diagnosis
  • Leiomyomatosis* / enzymology
  • Leiomyomatosis* / pathology
  • Neoplastic Syndromes, Hereditary* / diagnosis
  • Neoplastic Syndromes, Hereditary* / enzymology
  • Neoplastic Syndromes, Hereditary* / pathology
  • Prognosis
  • Uterine Neoplasms* / diagnosis
  • Uterine Neoplasms* / enzymology
  • Uterine Neoplasms* / pathology

Substances

  • Fumarate Hydratase